Lumos seeking to light the way with drug for ultra-rare CTD
By Marie Powers
Monday, February 24, 2014
The ultra-rare disease creatine transporter deficiency (CTD) wreaks havoc on its patient population of young boys. The x-linked autism spectrum disorder prevents the transport of creatine – a nitrogenous organic acid that serves as fuel for the body’s cells – into the brain, causing patients to suffer seizures, speech delay, behavioral abnormalities and severe cognitive impairment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.